ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2166

Work Productivity in Newly Diagnosed, Untreated Rheumatoid Arthritis Patients

Siri Lillegraven1, Nina P. Sundlisæter1, Anna-Birgitte Aga1, Inge C Olsen1, Till Uhlig2, Tore K. Kvien1, Espen A. Haavardsholm1 and The ARCTIC study group, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Diakonhjemmet Hospital, Oslo, Norway

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Early Rheumatoid Arthritis and Work Disability

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: ACR/ARHP Combined Abstract Session: Epidemiology and Pubic Health

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:Rheumatoid
arthritis (RA) is a known cause of work productivity loss. The goal within
rheumatology today is to diagnose RA as soon as possible, to allow for early and
aggressive treatment aiming for remission and sustained levels of daily
activities. The objective of the current study was to assess work participation
in an early, untreated RA cohort, and assess if work productivity differed
across groups of patients according to disease activity.

Methods: Consecutive RA patients who fulfilled the 2010 ACR/EULAR classification criteria were recruited between
October 2010 and April 2013. All patients had symptom duration <2 years from
first swollen joint, and were disease modifying anti-rheumatic drug (DMARD)
na•ve with indication for DMARD treatment at time of inclusion. The data
collection included clinical examination, patient
reported outcome measures (e.g. Work Productivity and Activity Impairment
Questionnaire, WPAI) and laboratory assessment. We
used data from WPAI and additional information on
work participation to assess absenteeism (work time missed), presenteeism (impairment while at work) and overall work
productivity loss (absenteeism plus presenteeism) due
to RA. We then compared work participation across disease activity groups by
Mann-Whitney U-test or chi-square test as appropriate.

Results: A
total of 233 patients were included with median (25th percentile, 75th percentile) age 53.9 (41.7,
62.5) years, median disease duration from first swollen joint 5.7 (2.8, 10.2)
months, 61.8 % female gender and 82.0% anti-citrullinated
protein antibody (ACPA) positivity. 176 patients
(75.5%) reported current employment (Table).
Patients not reporting employment were retired (49.1%), on disability pension
(19.3%) or unemployed for other reasons (31.6%). Although employed patients
overall had limited absenteeism and moderate work productivity loss, patients
with high disease activity had higher levels of absenteeism (median 71.4% vs 0.0%, p-value<0.001), presenteeism
(40.0% vs. 10.0%, p-value < 0.01) and had impaired overall work productivity
(85.7% vs. 50.0%, p-value <0.001) compared to patients in low disease
activity (Table). There were no
significant differences between groups with regards to age, gender, ACPA positivity and disease duration.

All patients

(n=233)

Low disease activity

(n=33)

Moderate disease activity (n=103)

High disease activity

(n=85)

Female %(n)

61.8 (144)

69.7 (23)

61.1 (63)

60.5 (52)

Age*

53.9 (41.7, 62.5)

52.2 (40.0, 62.7)

51.9 (40.4, 61.6)

55.3 (47.0, 62.9)

ACPA+ %(n)

82.0 (191)

84.9 (28)

87.4 (90)

75.3 (64)

Time since first swollen joint, months*

5.7 (2.8, 10.2)

7.2 (4.0, 9.9)

6.1 (3.4, 11)

4.2 (2.6, 9.6)

EQ-5D*

0.66 (0.23, 0.73)

0.73 (0.59, 0.80)

0.69 (0.52, 0.76)

0.52 (0.06, 0.66)

Currently employed %*

75.5 (176)

72.7 (24)

78.6 (81)

70.1 (60)

Absenteeism %*

0.0 (0.0, 100.0)

0.0 (0.0, 10.0)

0.0 (0.0, 50.0)

71.4 (0.0, 100.0)¤

Presenteeism %*

30.0 (10.0, 50.0)

10.0 (0.0, 40.0)

30.0 (10.0, 40.0)

40.0 (20.0, 60.0)#

Overall work impairment due to RA %*

50 (20.0, 100.0)

27.7 (0.0, 50.0)

40.0 (20.0, 70.0)

85.7 (50.0, 100.0)¤

# p-value <0.05 when compared to patients in low disease activity ¤ p-value<0.001 *Median (25th percentile, 75th percentile) Disease activity groups were defined according to disease activity score (DAS): low disease activity = DAS 1.6-2.4, moderate disease activity = DAS 2.4-3.7, high disease activity = DAS>3.7.

Conclusion: Newly diagnosed DMARD-na•ve RA patients on average
had low levels of absenteeism, but about half the patients had work impairment
due to either absenteeism or presenteeism. Patients
with high disease activity had higher levels of absenteeism, presenteeism and overall work impairment than patients with
low disease activity. The data suggest that the 2010 ACR/EULAR classification criteria might capture RA patients
with short symptom duration before significant loss of work productivity, but
that even in this group many patients have already experienced work impairment
due to their disease.


Disclosure: S. Lillegraven, None; N. P. Sundlisæter, None; A. B. Aga, None; I. C. Olsen, None; T. Uhlig, None; T. K. Kvien, None; E. A. Haavardsholm, AbbVie, 2,Pfizer Inc, 2,MSD, 2,Roche Pharmaceuticals, 2,UCB, 2.

To cite this abstract in AMA style:

Lillegraven S, Sundlisæter NP, Aga AB, Olsen IC, Uhlig T, Kvien TK, Haavardsholm EA. Work Productivity in Newly Diagnosed, Untreated Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/work-productivity-in-newly-diagnosed-untreated-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/work-productivity-in-newly-diagnosed-untreated-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology